News Details

View all news

Mirati Therapeutics to Voluntarily Delist from TSX

7/19/2013

San Diego, California, July 19, 2013 – Mirati Therapeutics, Inc. (“Mirati Therapeutics”) today announced that, consistent with its previously disclosed plans, it has applied to the Toronto Stock Exchange (“TSX”) to voluntarily delist from trading its shares of common stock.  Effective at market close on July 26, 2013, Mirati’s common stock will no longer be traded through the facilities of the TSX.  Mirati’s shares of common stock are currently traded, and will continue to be traded, on the NASDAQ Capital Market (“NASDAQ”), under the ticker symbol “MRTX”.

 “The listing on the NASDAQ exchange is the culmination of a series of strategic restructuring steps that were designed to improve the investment profile of Mirati Therapeutics and enable us to aggressively pursue the development of our novel therapies for the treatment of cancer patients,” said Dr. Charles Baum, President and CEO.

About Mirati Therapeutics

Mirati Therapeutics is a publicly-traded biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Our compounds result from internal chemistry efforts targeting the active sites of enzymes that are key drivers of tumor growth. Our highly targeted clinical development programs are focused on treating selected tumor types that express high levels or key driver mutations of these targets in order to most effectively address unmet patient needs. Our lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. We are also evaluating development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma and MGCD516, a unique kinase inhibitor with a distinct target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics shares are traded on the NASDAQ (symbol “MRTX”) and the Toronto Stock Exchange (symbol “MYG”).

Notice to Investors

This news release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities.

Investor Relations Contacts

Mark J. Gergen
Executive Vice President & COO
Mirati Therapeutics, Inc.
Tel.: 858.535.2075
ir@mirati.com
mirati.com

Michael Wood
Managing Director
LifeSci Advisors
Tel.: 646.597.6983
mwood@lifesciadvisors.com
www.lifesciadvisors.com


Tracey Rowlands, PhD
Director of Investor Relations and Business Development
Mirati Therapeutics, Inc.
Tel.: 514.337.3333 ext. 512
ir@mirati.com
mirati.com

Categories: Press Releases
View all news